Navigation Links
Sigma-Aldrich Corporation Announces New Credit Facility

ST. LOUIS, May 16, 2012 /PRNewswire/ -- Sigma-Aldrich announced today that it has established a new $600 million revolving credit facility that will mature on May 10, 2017.  The new facility replaces a $450 million revolving credit facility that was scheduled to mature on December 11, 2012.  The $600 million facility will provide back-up liquidity for the commercial paper program and be used for general corporate purposes.

Wells Fargo Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and J.P. Morgan Securities LLC served as co-lead arrangers for the nine-bank syndicate participating in this facility.  Wells Fargo Bank, National Association acted as the administrative agent.

About Sigma-Aldrich:  Sigma-Aldrich (Ticker SIAL) is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 40 countries and has nearly 9,000 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology.  For more information about Sigma-Aldrich, please visit its website at

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region
2. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
3. Sigma-Aldrich (NASDAQ: SIAL) Declares Quarterly Dividend.
4. Sigma-Aldrich Acquires Vetec Quimica Fina Ltda
5. Sigma-Aldrich Announces Organizational Changes
6. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
7. Sigma-Aldrich to Present at the JP Morgan 29th Annual Healthcare Conference on Monday, January 10, 2011.
8. Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio
9. Sigma-Aldrich Corporation Announces Death of Chairman and CEO; Election of New CEO and Chairman; Conference Call Scheduled for 10:00a.m. (Central Time) on November 15, 2010
10. Sigma-Aldrich Announces Pricing of Senior Notes
11. Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 -
Post Your Comments:
(Date:11/30/2015)... 30, 2015  AbbVie, is introducing Good Morning ... a daily routine for managing the life-long condition of ... affect the way the body absorbs it so resources ... daily routine are important. The goal of the new ... manage their hypothyroidism by establishing a daily routine, spirit ...
(Date:11/30/2015)... HACKENSACK, N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI ), a leading developer of ... its wholly-owned subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded ... Office of the Chief Scientist (OCS). This grant, ... to Brainstorm for 2015 activities to approximately $1.8 million (approximately ...
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
Breaking Biology Technology:
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
Breaking Biology News(10 mins):